Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.7M | $15.3M | $25.5M | $31.0M |
| Cost of revenue | $23.0K | $126.0K | $127.0K | $503.0K | $50.5M | $1.5M | $340.0K | $1.9M |
| Gross profit | −$23.0K | −$126.0K | −$127.0K | −$503.0K | −$48.8M | $13.9M | $25.1M | $29.1M |
| Gross margin | — | — | — | — | -2839.8% | 90.4% | 98.7% | 93.8% |
| R&D | $22.0M | $12.4M | $28.4M | $43.0M | $51.1M | $73.5M | $79.9M | $99.4M |
| Operating income | −$28.2M | −$19.0M | −$37.2M | −$54.4M | −$67.9M | −$96.9M | −$112.8M | −$131.5M |
| EBITDA | −$28.2M | −$18.6M | −$36.6M | −$53.9M | −$66.9M | −$95.5M | −$5.1M | −$125.5M |
| Net income | −$28.6M | −$18.9M | −$36.7M | −$53.8M | −$66.6M | −$101.7M | −$19.8M | −$141.4M |
| Net margin | — | — | — | — | -3879.0% | -662.5% | -77.8% | -456.3% |
| EPS (diluted) | -5.88 | -3.21 | -3.59 | -3.95 | -2.44 | -2.77 | -0.51 | -2.63 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $61M | $-0.21 | $-0.35–$0.06 | 4 |
| 2027 | $83M | $0.18 | $-0.17–$0.55 | 4 |
| 2028 | $105M | $0.39 | $0.39–$0.39 | 3 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds MRNS.
No tracked institution reports a position in MRNS as of their last filing.
| Execution date | Ratio |
|---|---|
| 2020-09-23 | 1-for-4reverse |
No one on the platform has traded MRNS yet.
| $28M |
| — |
| HEXOHEXO Corp. | $0.71 | +2.45% | $31M | — |
| IRDOpus Genetics, Inc. | $4.06 | +1.50% | $335M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.8× sales vs its 13.3× historical median P/S.
Fair value ≈ $9.15 · price $0.55 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
@CapitalismUSA @Theverypatientone In terms of EV for LNP $ABUS will get about 35%-40% and $ROIV 65%-60%. $140B * .12*.35 = $6B at the very minimum and as high as mid to high teens if $MRNS, $BNTX, $PFE dare to gamble and go to trail.
View on StockTwits ↗#SPMNOTES EXAMPLES OF G-101 SPM AI's STOCK PICKS As of January 2026, the G-101 SPM AI algorithm, co-authored by Christopher Netelkos at Northridge Company, has documented a certified history of 3,097 stock picks since its inception in March 2023. The following are documented examples of stocks selected by the algorithm and their subsequent performance: Documented Winners (Historical to 2026) According to performance audits and strategy reports published in January 2026, the AI identified several major individual winners before significant rallies: Thyssenkrupp (ETR: TKAG): Gained +223% after being selected by the AI. Super Micro Computer (NASDAQ: $SMCI): Achieved a +185.8% return while active in the AI's strategy. ABL Bio Inc (KQ: 298380): Increased by +170.30% following its selection. ViaSat Inc (NASDAQ: $VSAT): Saw a +163% rise after being picked. Colab Cloud Platforms (BO: COLA): Gained +111.80%. Banco Santander (NYSE: SAN): Achieved a +104.45% return. Nvidia (NASDAQ: $NVDA): Recorded a +226.7% gain while held within the AI strategy. Specific Case Study: Marinus Pharmaceuticals ($MRNS) A notable 2024–2025 case study from Christopher Netelkos’s "SPM Notes" highlights the algorithm's timing: The AI issued a bid at $1.50. The position was exited on January 29, 2024, at $10.26 after the "SPM tag" dropped, representing a substantial gain before the subsequent stock decline. Current Strategy Performance (January 2026) As of early January 2026, the AI's "Top Value" strategy has reportedly delivered an 83.20% return, outperforming its benchmark by 33.85%. The algorithm continues to process information from 145 unstructured data sources to identify "smart" data trends that prioritize non-human intervention over traditional conventional analytics.
View on StockTwits ↗GLMD meets a lot of criteria 🔥 Biotech history shows what’s possible when the right setup meets the right spark… 📈 $RCUS — $2 to $25+ on oncology momentum 📈 $CRBP — $0.90 to $9+ on FDA buzz 📈 $XBIO — under $1 to $6+ on low-float madness 📈 $MRNS — $1.50 to $13+ on epilepsy pipeline news ⬇️⬇️⬇️⬇️ Now look at $GLMD 🔹 Trading under $2 🔹 Book value near $12 🔹 Strong cash position 🔹 Biotech catalyst potential 🔹 Tight float 👀 Not a guarantee. Not advice. Just perspective. In biotech land, moves like these have happened before. GLMD has the ingredients. Now it’s about the catalyst.
View on StockTwits ↗@IMADORK and what about $MRSN in 2021?. It woul be better to tell the whole story. $MRNS now: 0,52$.
View on StockTwits ↗$MRNS CEO purchased 5,933 shares at $1.10 for a total of $6,526. Braunstein Scott now owns 304,600 shares. https://ceo-buys.com
View on StockTwits ↗$MRNS someone please teach the fucking kid to say “please”.. or cry motherfather, then I may buy 1 coin 🤣🤣🤣🤣🤣🤣🤣🤣🤣
View on StockTwits ↗$MRNS Nasdaq says it will be suspended, not delisted. It hopefully gets back active with a new symbol. Could be hugeeeee 🤞☀️🫶
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.